Eli Lilly Acquires Merida Biosciences in Deal Worth Up to $2.875B
Eli Lilly is buying Merida Biosciences in an all-cash deal valued at up to $2.875 billion, expanding its pipeline.
Eli Lilly announced Monday it will acquire Merida Biosciences in an all-cash transaction worth up to $2.875 billion, signaling the pharmaceutical giant's continued push to broaden its drug development portfolio through targeted dealmaking.
The acquisition price of up to $2.875 billion suggests a milestone-based structure, a common arrangement in biotech buyouts where a portion of the payout is contingent on the acquired company's pipeline candidates hitting specific clinical or regulatory targets. Lilly has not publicly disclosed the breakdown between upfront consideration and potential milestone payments.
Read more OpenAI Ad Business Crosses $1 Billion in Annual Revenue →
The deal reflects Lilly's broader strategic posture in recent years: deploying substantial capital to secure promising early- and mid-stage biotechs rather than building every asset internally. The company has been among the most acquisitive large-cap pharmaceutical firms, leveraging blockbuster revenue from its diabetes and obesity franchises to fund external growth.
Merida Biosciences, the target company, operates in an area of active drug discovery, and the acquisition is expected to add meaningful pipeline depth for Lilly. Terms beyond the total transaction value have not been fully disclosed in initial reports, and regulatory review timelines have not yet been announced.
The announcement underscores the ongoing consolidation wave sweeping the biopharma sector as large companies race to replenish pipelines ahead of patent cliffs and capitalize on advances in drug science. Continue reading at SeekingAlpha.
